Search Results

Business

Stablix, Inc. today announced the appointment of Tony Kingsley as Chief Executive Officer.

February 14, 2022

·

2 min read

Business

Stablix Appoints Eddine Saiah Chief Scientific Officer and Expands Leadership Team

Stablix, Inc., a biopharmaceutical company pioneering targeted protein stabilization (TPS) as a novel therapeutic modality, today announced that Eddine Saiah, Ph.D., has joined the company as Chief Scientific Officer.

May 26, 2022

·

3 min read

Business

Stablix Therapeutics Launches with $63 Million Series A Financing

Stablix Therapeutics, a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS), today announced a $63 million Series A financing led by founding investor Versant Ventures together with NEA, Cormorant, Euclidean Euclidean Capital and Alexandria Real Estate Equities.

June 3, 2021

·

6 min read

Press Releases

Peptone Announces Key Leadership Appointments to Progress Novel Protein Structural Insights for Intrinsically Disordered Protein-Driven Therapeutics

January 10, 2025

·

5 min read

Business

Three Biopharma Companies Raise Millions in Separate Series A Financing Rounds

The three companies will aim to develop their different programs such as Stablix TPS platform, Stellanova’s focused on targeting pro-tumorigenic effects, and Amyl’s development of preclinical therapeutic candidates.

June 4, 2021

·

3 min read

·

Alex Keown

Press Releases

Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board

November 11, 2024

·

6 min read

Press Releases

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

November 13, 2024

·

10 min read

Money on the Move: June 2-8

Things are warming up quickly this summer for life sciences investors. Here’s who’s coming in hot with cash this week.

June 9, 2021

·

4 min read

·

Kate Goodwin

Business

Deerfield-Backed Vicinitas Launches to Target Key Protein Stabilization

Vicinitas launched with a Series A round worth $65 million and was co-led by a16z and Deerfield Management, with participants including Droia Ventures, GV, and the Berkeley Catalyst Fund.

August 1, 2022

·

3 min read

·

Mark Terry

Deals

Versant Ventures Announces Acquisition of Portfolio Company Vividion Therapeutics

Versant Ventures announced that portfolio company Vividion Therapeutics has been acquired by Bayer AG for $1.5 billion up front and up to $500 million in potential future milestone payments.

August 5, 2021

·

2 min read